Drugs

CDER is engaged in essential COVID-19 activities to protect and promote public health

Ranging from the acceleration of development for treatments for COVID-19, maintaining and securing drug supply chains, providing guidance to manufacturers, advising developers on how to handle clinical trial issues, and keeping the public informed

Learn More

COVID-19 drug approved for hospitalized patients age 12 and older

Oct 22 - Emergency use authorization (EUA) continues access for hospitalized patients under age 12

Nonsteroidal anti-inflammatory drugs (NSAIDs) can harm unborn babies

Oct 15 - Avoid taking NSAIDs like ibuprofen at 20 weeks or later in pregnancy

National Prescription Drug Take Back Day is October 24

Oct 15 – Find a location to safely dispose of unwanted or expired medicines

Drug Information, Safety, and Availability

Medication Guides, Drug Safety Communications, Shortages, Recalls

Drug Approvals and Databases

Drugs@FDA, Orange Book, National Drug Code, Recent drug approvals

Drug Development and Review Process

Drug applications, submissions, manufacturing, and small business help

Guidance, Compliance, and Regulatory Information

Guidances, warning letters, drug compounding, international information, registration and listing

Regulatory Science and Research

CDER research programs, initiatives, and resources

Emergency Preparedness

Prepare and respond to natural disasters, nuclear and chemical attacks

Updates, News, and Events

Recent approvals, meetings, workshops, blogs, podcasts, stay connected

About the Center for Drug Evaluation and Research (CDER)

Our role, mission, organization, history, leadership, job openings

Consumers and Patients

FAQs about hand sanitizers. Find drug information. Report drug side effects. Learn how to buy, use, and dispose of unused drugs. Attend a public meeting.